SBC-115337 

SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC₅₀ value of 0.5 μM^[1][2].

IC50: 0.5 μM (PCSK9)^[1]

The potent compound (SBC-115,337) shows an IC50 of 0.6 μM measured in an in vitro ELISA assay to monitor the effect of PCSK9 binding to the recombinant LDLR. SBC-115,337 at 1.2 μM induces more than tenfold upregulation of LDLR in HepG2 cells with respect to the control, increases uptake of fluorescently labeled DiI-LDL and loweres LDL-c levels in mice fed a high-fat diet^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

473.48

C₂₉H₁₉N₃O₄

423148-46-3

Solid

Light yellow to brown

O=C(C1=CC2=CC=CC=C2O1)NC3=CC=C(C(NC4=CC=C(C5=NC6=CC=CC=C6O5)C=C4)=O)C=C3

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Xu S, et al. Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur J Med Chem. 2019;162:212-233.  [Content Brief]

  [2]. Lavecchia A, et al. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future Med Chem. 2019;11(5):423-441.  [Content Brief]